^
    2d
    Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL (clinicaltrials.gov)
    P2, N=50, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • Inokai (orelabrutinib)
    2d
    Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P3, N=94, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate)
    2d
    OASIS-II: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=194, Active, not recruiting, The Lymphoma Academic Research Organisation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib)
    3d
    NX-5948-201: A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a Bcell Lymphoma-2 Inhibitor (BCL-2i) (DAYBreak CLL-201) (2025-521088-10-00)
    P1/2, N=41, Recruiting, Nurix Therapeutics Inc.
    New P1/2 trial
    |
    bexobrutideg (NX-5948)
    3d
    CLOU064P12301: A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis (2025-521546-23-00)
    P2/3, N=279, Not yet recruiting, Novartis Pharma AG
    New P2/3 trial
    |
    Rhapsido (remibrutinib)
    3d
    DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, Dizal Pharmaceuticals | Trial completion date: Aug 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    birelentinib (DZD8586)
    3d
    A041702: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P3, N=465, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Dec 2026
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    3d
    A case report of lymphoplasmacytic lymphoma with spherocytosis. (PubMed, Open Life Sci)
    The patient's condition stabilized following targeted therapy with zanubrutinib and rituximab (ZR regimen). This case underscores the complexity of diagnosing dual hematological anomalies, highlights the importance of multidisciplinary collaboration, and seeks to explore the potential pathophysiological link between LPL and spherocytosis, offering a reference for diagnosis and treatment in similar clinical scenarios.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib)
    3d
    Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas (clinicaltrials.gov)
    P2, N=15, Recruiting, Baptist Health South Florida | Trial completion date: Feb 2031 --> Feb 2033 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    pemetrexed • Brukinsa (zanubrutinib)
    3d
    A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines (clinicaltrials.gov)
    P3, N=362, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Aug 2028 --> Jun 2029
    Trial completion date • Pan tumor
    |
    Rhapsido (remibrutinib)
    4d
    LOXO-BCL-20001: Study of Oral LOXO-338 in Patients With Advanced Blood Cancers (clinicaltrials.gov)
    P1, N=316, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    Chr t(11;14)
    |
    Jaypirca (pirtobrutinib) • FCN-338
    4d
    MZL-IIT-O: Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL (clinicaltrials.gov)
    P2, N=30, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Inokai (orelabrutinib)